

Research:

An important goal of the Center is to enable other patients beyond Silver Hill to achieve similar positive outcomes. Dr. Marotta and his team have made substantial progress toward that goal with various publications, presentations, and professional development efforts.

Already, the Center has already made substantial progress toward this goal. Dr. Marotta's work has included many publications and presentations of his specific treatment protocol:

Publications:

Marotta R, Buono F, Garakani A, Collins E, Cerrito B, Rowe D. The effects of augmenting clozapine with oxytocin in schizophrenia: An initial case series. *Annals of Clinical Psychiatry*, 2020, 32: 90-96.

Garakani A, Buono FD, Marotta RF. Sublingual oxytocin with clozapine in a patient with persisting psychotic symptoms, suicidal thinking with self-harm. *Journal of Clinical Psychopharmacology*, 2020, 40(5): 507-509.

Marotta R, Cutts Dougherty K, Bihl I, Rowe D, Garakani A, Buono FD. (2020). *Can Augmented Sublingual Oxytocin Decrease Negative Symptoms within Treatment Resistant Schizophrenic Populations: A Pilot Study*. Congress of the Schizophrenia International Research Society. <https://doi.org/10.1093/schbul/sbaa029.758>

Marotta R, Cerrito B, Rowe D, Collins ED, O'Connell J, Garakani A, Buono FD. (2019). *Concurrent usage of sublingual oxytocin and clozapine to treat the positive and negative symptoms within individuals with treatment resistant schizophrenia*. Congress of the Schizophrenia International Research Society, Orlando, FL. <https://doi.org/10.1093/schbul/sbz018.520>

Presentations:

Marotta, R., Cutts Dougherty, K., Buono, F., Garakani, A., Brown, M., Stacy, W., & Mann, L. Long Term Effects of Clozapine and Oxytocin on Functional Recovery and Sobriety Maintenance in Treatment Resistant Schizophrenia (2022). *2022 Congress of the Schizophrenia International Research Society, Oral Presentation*.

Frances, R. (Chair), Levin, F. (Co-Chair), Marotta, R. (Presenter), Addressing the Common Course of Schizophrenia: Effect of Clozapine and Sublingual Oxytocin on Substance Use Relapse and Long- Term Life Trajectories. American Academy of Addiction Psychiatry 2021 Annual Meeting and Scientific Symposium - December 10, 2021.

Marotta, R. Oxytocin as an Augmentation to the Treatment of Schizophrenia with Clozapine: Improvement in Negative Symptoms and Life Paths. New York Presbyterian Westchester, May 26, 2021

Marotta, R. Oxytocin as an Augmentation to the Treatment of Schizophrenia with Clozapine: Improvement in Negative Symptoms and Life Paths. Grand Rounds Presentation, Silver Hill Hospital. March 17, 2021

Marotta, R. Oxytocin as an Augmentation to the Treatment of Schizophrenia with Clozapine: Improvement in Negative Symptoms and Life Paths. Grand Rounds Presentation, Institute of Living, Hartford Hospital. January 7, 2021.

Marotta, R., Cutts Dougherty, K., Bihl, I., Rowe, D., Garakani, A., & Buono, F. D. Can Augmented Sublingual Oxytocin Decrease Negative Symptoms within Treatment Resistant Schizophrenic Populations: A Pilot Study. (2020). *2020 Congress of the Schizophrenia International Research Society, Poster Presentation.*

Virgil Stucker Mental Horizons Podcast, Season 3, Episode 3: Creative Psychiatry: Learn about the benefits of oxytocin for psychosis – Dr. Rocco Marotta.

<https://www.virgilstuckerandassociates.com/post/season-3-episode-3-creative-psychiatry-learn-about-the-benefits-of-oxytocin-for-psychosis>

Professional Development:

Dr. Marotta and his team also conduct a monthly Neuropsychiatric Case Conference Program for Silver Hill Hospital clinicians. This program increases clinical understanding of treating patients with persistent psychotic illness, especially those who have failed multiple interventions.

These presentations and educational efforts have spurred interest in Dr. Marotta's methods and resulted in three important new partnerships:

Dr. Mercedes Perez-Rodriguez, MD, PhD at Mount Sinai Hospital

The Center has funded a collaboration with Dr. Perez Rodriguez to study the absorption of sublingual oxytocin in the bloodstream. Approved by the Mount Sinai Institutional Review Board (IRB), this study will soon begin enrolling participants.

Dr. Michael McGee, MD – Atascadero State Hospital

Dr. Marotta and his team are collaborating with Dr. McGee to conduct a feasibility study of this forensic hospital's patients who have been stabilized on clozapine to explore whether adding oxytocin, sublingually, can increase overall psychosocial functioning that allows a higher percentage of patients to return to community life. The study protocol has been submitted to the IRB for review. Peter Fonagy, OBE, FBA, FAcSS, FMedSci, University College London, and Frank Buono, Ph.D., Yale University are also part of this research team.

Sage Healthcare Clinic is an academically supported organization that strives to provide best practices in a holistic care environment including Family Practice, Behavioral and Mental Health, Social Work, and Case Management. This clinic is attached to Bridgeport Rescue Mission, in Bridgeport, Connecticut